# US 2015/0031719 A1 · Topical Therapy for the Treatment of Migraines, Muscle Sprains, Muscle Spasms, Spasticity and Related Conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031719 A1
- Document ID: US20150031719A1
- Status: Published application
- Kind: A1
- Application number: 14/511,277
- Filed: 2014-10-10
- Published: 2015-01-29
- Earliest claimed: 2003-06-20
- Assignees: Afgin Pharma, LLC
- Applicants: Afgin Pharma LLC
- Inventors: Ronald AUNG-DIN
- Web page: https://patentgrep.com/patent/US20150031719A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/433: Thidiazoles
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/06: Antimigraine agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.

## Claims

### Claim at position 1

1-73. (canceled)

### Claim 74

A method of treating migraines, cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches and tension related migraines with a topical formulation comprising applying a therapeutically effective amount of an active agent(s) comprising a skeletal muscle relaxant or a pharmaceutically acceptable salt thereof onto the skin of a human patient experiencing an acute condition selected from the group consisting of migraine, cluster headache, muscle sprain, muscle spasm, spasticity, tension headache and tension related migraine at the posterior cervical area in close proximity to the brain stem, such that the unit dose provides a therapeutic effect within about 15 to about 30 minutes after topical administration to the human patient.

### Claim 75 (depends on 74)

The method of claim 74, further comprising applying a therapeutically effective amount of a serotonin agonist onto the skin of a human patient experiencing an acute condition selected from the group consisting of migraine, cluster headache, muscle sprain, muscle spasm, spasticity, tension headache and tension related migraine at the posterior cervical area in close proximity to the brain stem.

### Claim 76 (depends on 74)

The method of claim 74, further comprising applying a therapeutically effective amount of an ergot alkaloid onto the skin of a human patient experiencing an acute condition selected from the group consisting of migraine, cluster headache, muscle sprain, muscle spasm, spasticity, tension headache and tension related migraine at the posterior cervical area in close proximity to the brain stem.

### Claim 77 (depends on 74)

The formulation of claim 74, wherein the skeletal muscle relaxant is selected from the group consisting of afloqulone, baclofen, botulin toxins, carisoprodol, chlormezanone, chlorphenesin carbamate, chlorzoxasozone, cyclobenzaprine, clonazepam, dantrolene, diazepam, eperisone, idrocilamide, inaperisone, mephenesin, mephenoxalone, methocarbamol, metaxalone, mivacurium chloride, orphenadrine, phenprobamate, pridinol mesylate, quinine, tetrazepam, thiocolchicoside, tizanidine, tolperisone, pharmaceutically acceptable salts thereof, active metabolites thereof, prodrugs thereof and mixtures thereof.

### Claim 78 (depends on 75)

The method of claim 75, wherein the serotonin agonist is selected from the group consisting of sumatriptan, naratriptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 79 (depends on 76)

The method of claim 76, wherein the ergot alkaloid is selected from the group consisting of bromocriptine, ergocristine, ergocristinine, ergotamine, ergotaminine, ergocryptine, ergocryptinine, ergocornine, ergocorninine, ergosine, ergosinine, ergonovine, ergometrinine, dihydroergotamine, lisuride, d-lysergic acid, d-isolysergic acid, lysergol, lergotrile, metergoline, methysergide, methylergonovine, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 80 (depends on 74)

The method of claim 74, further comprising applying a unit dose of a therapeutically effective amount of a serotonin agonist and an effective amount of an ergot alkaloid onto the skin of a human patient experiencing an acute condition selected from the group consisting of migraine, cluster headache, muscle sprain, muscle spasm, spasticity, tension headache and tension related migraine at the posterior cervical area in close proximity to the brain stem.

### Claim 81 (depends on 80)

The method of claim 80, wherein the skeletal muscle relaxant is selected from the group consisting of afloqulone, baclofen, botulin toxins, carisoprodol, chlormezanone, chlorphenesin carbamate, chlorzoxasozone, cyclobenzaprine, clonazepam, dantrolene, diazepam, eperisone, idrocilamide, inaperisone, mephenesin, mephenoxalone, methocarbamol, metaxalone, mivacurium chloride, orphenadrine, phenprobamate, pridinol mesylate, quinine, tetrazepam, thiocolchicoside, tizanidine, tolperisone, pharmaceutically acceptable salts thereof, active metabolites thereof, prodrugs thereof and mixtures thereof.

### Claim 82 (depends on 81)

The method of claim 81, wherein the serotonin agonist is selected from the group consisting of sumatriptan, naratriptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 83 (depends on 82)

The method of claim 82, wherein the ergot alkaloid is selected from the group consisting of bromocriptine, ergocristine, ergocristinine, ergotamine, ergotaminine, ergocryptine, ergocryptinine, ergocornine, ergocorninine, ergosine, ergosinine, ergonovine, ergometrinine, dihydroergotamine, lisuride, d-lysergic acid, d-isolysergic acid, lysergol, lergotrile, metergoline, methysergide, methylergonovine, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 84 (depends on 74)

The method of claim 74, further comprising incorporating the active agent into an aqueous based formulation.

### Claim 85 (depends on 74)

The method of claim 74, further comprising preparing the topical formulation in a form selected from the group consisting of a liquid, a semisolid, a solid and mixtures thereof.

### Claim 86 (depends on 74)

The method of claim 74, further comprising incorporating a therapeutic amount of active agent(s) into the unit dose such that the active agent(s) would provide a subtherapeutic plasma level if orally administered, but are therapeutically effective when administered topically at the posterior cervical area.

### Claim 87 (depends on 74)

The method of claim 74, wherein skeletal muscle relaxant comprises from about 0.2 mg to about 8 mg of tizanidine hydrochloride.

### Claim 88 (depends on 74)

The method of claim 74, wherein the skeletal muscle relaxant comprises cyclobenzaprine.

### Claim 89 (depends on 75)

The method of claim 75, wherein the serotonin agonist comprises sumatriptan.

### Claim 90 (depends on 75)

The method of claim 75, wherein the serotonin agonist comprises from about 0.5 mg to about 200 mg sumatriptan.

### Claim 91 (depends on 76)

The method of claim 76, wherein the therapeutically effective amount of ergot alkaloid ranges from about 0.1 mg to about 10 mg.

### Claim 92

A method of treating migraines, cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches and tension related migraines with a topical formulation comprising applying a therapeutically effective amount of a skeletal muscle relaxant or a pharmaceutically acceptable salt thereof incorporated into an immediate release pharmaceutically acceptable carrier onto the skin of a human patient at the posterior cervical area in close proximity to the brain stem, wherein the human patient is experiencing an acute condition selected from the group consisting of migraine, cluster headache, muscle sprain, muscle spasm, spasticity, tension headache and tension related migraine, such that the unit dose provides a therapeutic effect within about 30 minutes after the topical administration.

### Claim 93 (depends on 92)

The method of claim 92, further comprising applying an additional therapeutically effective amount of the skeletal muscle relaxant onto the skin of the human patient at the posterior cervical area from about 15 minutes to about 3 hours after the first application of the unit dose.

### Claim 94 (depends on 92)

The method of claim 92, further comprising applying a therapeutically amount of a serotonin agonist onto the skin of a human patient at the posterior cervical area in close proximity to the brain stem.

### Claim 95 (depends on 92)

The method of claim 92, further comprising applying a therapeutically effective amount of an ergot alkaloid onto the skin of a human patient at the posterior cervical area in close proximity to the brain stem.

### Claim 96 (depends on 92)

The method of claim 92, wherein the skeletal muscle relaxant is selected from the group consisting of afloqulone, baclofen, botulin toxins, carisoprodol, chlormezanone, chlorphenesin carbamate, chlorzoxasozone, cyclobenzaprine, clonazepam, dantrolene, diazepam, eperisone, idrocilamide, inaperisone, mephenesin, mephenoxalone, methocarbamol, metaxalone, mivacurium chloride, orphenadrine, phenprobamate, pridinol mesylate, quinine, tetrazepam, thiocolchicoside, tizanidine, tolperisone, pharmaceutically acceptable salts thereof, active metabolites thereof, prodrugs thereof and mixtures thereof.

### Claim 97 (depends on 94)

The method of claim 94, wherein the serotonin agonist is selected from the group consisting of sumatriptan, naratriptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 98 (depends on 95)

The method of claim 95, wherein the ergot alkaloid is selected from the group consisting of bromocriptine, ergocristine, ergocristinine, ergotamine, ergotaminine, ergocryptine, ergocryptinine, ergocornine, ergocorninine, ergosine, ergosinine, ergonovine, ergometrinine, dihydroergotamine, lisuride, d-lysergic acid, d-isolysergic acid, lysergol, lergotrile, metergoline, methysergide, methylergonovine, pharmaceutically acceptable salts thereof, and mixtures thereof.
